🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

218 results for “Merck” Clear

  1. CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 small molecule active

    1 trial

  2. CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  3. CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  4. DEXAMETHASONE , -, -, MK-1022

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 small molecule active

    1 trial

  5. DEXAMETHASONE , ENFORTUMAB VEDOTIN , -, PARACETAMOL , -, MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  6. DOCETAXEL , Ifinatamab Deruxtecan, Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. DOCETAXEL , PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , CETUXIMAB, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 small molecule active

    1 trial

  8. DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  9. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  10. DURVALUMAB , Ifinatamab Deruxtecan, MK-6070

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  11. ENFORTUMAB VEDOTIN , mRNA-4157, Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  12. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  13. Enpatoran placebo, Enpatoran, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  14. FLUOROURACIL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM FOLINATE , OXALIPLATIN , -, CALCIUM LEVOFOLINATE , PARACETAMOL , -, -, -, -, Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  15. Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  16. Ifinatamab Deruxtecan, DOCETAXEL , Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , GEMCITABINE , PACLITAXEL , FAMOTIDINE , MK-2870, PARACETAMOL , CISPLATIN , PEMETREXED , -, -

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, MK-4280A, TRETINOIN, MK-1308A, vibostolimab, Lenvatinib

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-7684A, MK-1308A, Belzutifan, MK-4280A, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline solution NACl 0.9%, mRNA-4157

    Merck Sharp and Dohme

    Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion., MK-3120, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources